Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vera Therapeutics Inc Cl A (NQ: VERA )

7.480 +0.350 (+4.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 591,966
Open 7.230
Bid (Size) 7.100 (6)
Ask (Size) 7.550 (1)
Prev. Close 7.130
Today's Range 7.120 - 7.680
52wk Range 5.200 - 24.94
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From Vera Therapeutics
Via Globe NewsWire
$12M Bet On Vera Therapeutics? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga

Performance

YTD
-59.13%
-59.13%
1 Month
-10.74%
-10.74%
3 Month
-60.02%
-60.02%
6 Month
-64.16%
-64.16%
1 Year
-64.92%
-64.92%

More News

Read More
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
From Vera Therapeutics
Via Globe NewsWire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Vera Therapeutics Stock Bolted Higher This Week
Via The Motley Fool
What 4 Analyst Ratings Have To Say About Vera Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock
From Vera Therapeutics
Via Globe NewsWire
Vera Therapeutics Releases Interim Analysis Of Rare Kidney Disease Drug, Deprioritizes Certain Phase 3 Programs
Via Benzinga
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria
From Vera Therapeutics
Via Globe NewsWire
Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)
From Vera Therapeutics
Via Globe NewsWire
5 Cheapest Health Care Stocks You Should Think About
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Vera Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Top 5 Health Care Stocks That May Surge
Via Benzinga
Dow Gains 150 Points After Fed Minutes
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Nasdaq Rises Over 100 Points; Crude Oil Drops Sharply
Via Benzinga
These 2 Nasdaq Biotechs Are Making Big Moves Wednesday
Via The Motley Fool
Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.